Handok

Handok Liabilities

The The Liabilities of Handok (002390.KS) as of Oct 31, 2026 is 512.43 B KRW. In the previous year, The Liabilities was 499.49 B KRW — a change of 2.59% (higher).

Liabilities

512.43 BKRW

YoY

2.59%

Last updated:

In 2025, Handok's total liabilities amounted to 512.43 B KRW, a 2.59% difference from the 499.49 B KRW total liabilities in the previous year.

The Handok Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
339.24 B KRW
Jan 1, 2019
404.67 B KRW
Jan 1, 2020
437.08 B KRW
Jan 1, 2021
457.57 B KRW
Jan 1, 2022
489.25 B KRW
Jan 1, 2023
449.71 B KRW
Jan 1, 2024
499.49 B KRW
Jan 1, 2025
512.43 B KRW
The Handok Liabilities history
YEARLiabilitiesYoY
512.43 BKRW+2.59%
499.49 BKRW+11.07%
449.71 BKRW-8.08%
489.25 BKRW+6.92%
457.57 BKRW+4.69%
437.08 BKRW+8.01%
404.67 BKRW+19.29%
339.24 BKRW-2.69%
348.63 BKRW+4.51%
333.60 BKRW+47.04%
226.88 BKRW+9.23%
207.71 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Handok Stock analysis

What does Handok do? Handok, Inc. generates revenue through the manufacture and sale of pharmaceutical products including Amaryl for diabetes, Tritace for hypertension and cardiovascular diseases, Teveten and Triapin for hypertension, Munobal for hypertension and stenocardia, Ketas for cerebral circulation issues, and Lasix for hypertension and edema. The company also sells over-the-counter pharmaceuticals, healthcare products, medical devices, diagnostic reagents, and vaccines. Additionally, Handok, Inc. earns income from real estate rental services. Its products target healthcare providers, hospitals, and pharmacies as key buyers within the pharmaceutical and healthcare sectors. The firm's product portfolio includes branded medications such as Amaryl, Tritace, Teveten, Triapin, Munobal, Ketas, and Lasix, which are distributed to medical professionals and retail pharmacies. Over-the-counter products and healthcare items are sold directly to consumers through retail channels. Medical devices and diagnostic reagents are supplied to healthcare facilities and laboratories. Vaccines are distributed to public health institutions and clinics. Handok, Inc. serves multiple market segments including diabetes management, cardiovascular care, hypertension treatment, and neurological health through its diverse product range. The company's real estate rental business supports its financial operations by providing steady income streams from leased properties. Key buyers include healthcare providers, pharmacies, hospitals, and public health institutions that purchase its branded pharmaceuticals and medical solutions. Handok is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Handok's Liabilities

Handok's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Handok's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Handok's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Handok's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Handok’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Handok stock

The Liabilities of Handok is 512.43 B KRW in 2025.

The Liabilities of Handok changed from 499.49 B KRW to 512.43 B KRW, representing a 2.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Handok since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Handok historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Handok

All Key Metrics — Handok